{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T14:51:29Z","timestamp":1787496689184,"version":"build-2736575974"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2019,11,28]],"date-time":"2019-11-28T00:00:00Z","timestamp":1574899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,11,28]],"date-time":"2019-11-28T00:00:00Z","timestamp":1574899200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2020,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The histone demethylase lysine-specific demethylase 1 (LSD1 or KDM1A) has emerged as a candidate therapeutic target in acute myeloid leukaemia (AML); tranylcypromine-derivative inhibitors induce loss of clonogenic activity and promote differentiation, in particular in the\n                    <jats:italic>MLL<\/jats:italic>\n                    -translocated molecular subtype of AML. In AML, the use of drugs in combination often delivers superior clinical activity. To identify genes and cellular pathways that collaborate with LSD1 to maintain the leukaemic phenotype, and which could be targeted by combination therapies, we performed a genome-wide CRISPR-Cas9 dropout screen. We identified multiple components of the amino acid sensing arm of mTORC1 signalling\u2014RRAGA, MLST8, WDR24 and LAMTOR2\u2014as cellular sensitizers to LSD1 inhibition. Knockdown of mTORC1 components, or mTORC1 pharmacologic inhibition, in combination with LSD1 inhibition enhanced differentiation in both cell line and primary cell settings, in vitro and in vivo, and substantially reduced the frequency of clonogenic primary human AML cells in a modelled minimal residual disease setting. Synergistic upregulation of a set of transcription factor genes associated with terminal monocytic lineage differentiation was observed. Thus, dual mTORC1 and LSD1 inhibition represents a candidate combination approach for enhanced differentiation in\n                    <jats:italic>MLL<\/jats:italic>\n                    -translocated AML which could be evaluated in early phase clinical trials.\n                  <\/jats:p>","DOI":"10.1038\/s41375-019-0659-6","type":"journal-article","created":{"date-parts":[[2019,11,28]],"date-time":"2019-11-28T09:03:54Z","timestamp":1574931834000},"page":"1266-1277","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Pre-clinical activity of combined LSD1 and mTORC1 inhibition in MLL-translocated acute myeloid leukaemia"],"prefix":"10.1038","volume":"34","author":[{"given":"Gauri","family":"Deb","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bettina","family":"Wingelhofer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio M. R.","family":"Amaral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alba","family":"Maiques-Diaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John A.","family":"Chadwick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary J.","family":"Spencer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma L.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui-Sun","family":"Leong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamara","family":"Maes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9188-4379","authenticated-orcid":false,"given":"Tim C. P.","family":"Somervaille","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,11,28]]},"reference":[{"key":"659_CR1","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.2217\/epi-2016-0009","volume":"8","author":"A Maiques-Diaz","year":"2016","unstructured":"Maiques-Diaz A, Somervaille TC. LSD1: biologic roles and therapeutic targeting. Epigenomics. 2016;8:1103\u201316.","journal-title":"Epigenomics"},{"key":"659_CR2","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.str.2011.01.001","volume":"19","author":"R Baron","year":"2011","unstructured":"Baron R, Binda C, Tortorici M, McCammon JA, Mattevi A. Molecular mimicry and ligand recognition in binding and catalysis by the histone demethylase LSD1-CoREST complex. Structure. 2011;19:212\u201320.","journal-title":"Structure"},{"key":"659_CR3","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1016\/j.molcel.2007.06.039","volume":"27","author":"S Saleque","year":"2007","unstructured":"Saleque S, Kim J, Rooke HM, Orkin SH. Epigenetic regulation of hematopoietic differentiation by Gfi-1 and Gfi-1b is mediated by the cofactors CoREST and LSD1. Mol Cell. 2007;27:562\u201372.","journal-title":"Mol Cell"},{"key":"659_CR4","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.ccr.2012.03.014","volume":"21","author":"WJ Harris","year":"2012","unstructured":"Harris WJ, Huang X, Lynch JT, Spencer GJ, Hitchin JR, Li Y, et al. The histone demethylase KDM1A sustains the oncogenic potential of MLL-AF9 leukemia stem cells. Cancer Cell. 2012;21:473\u201387.","journal-title":"Cancer Cell"},{"key":"659_CR5","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1038\/nm.2661","volume":"18","author":"T Schenk","year":"2012","unstructured":"Schenk T, Chen WC, Gollner S, Howell L, Jin L, Hebestreit K, et al. Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia. Nat Med. 2012;18:605\u201311.","journal-title":"Nat Med"},{"key":"659_CR6","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ccell.2015.06.002","volume":"28","author":"HP Mohammad","year":"2015","unstructured":"Mohammad HP, Smitheman KN, Kamat CD, Soong D, Federowicz KE, Van Aller GS, et al. A DNA Hypomethylation signature predicts antitumor activity of LSD1 inhibitors in SCLC. Cancer Cell. 2015;28:57\u201369.","journal-title":"Cancer Cell"},{"key":"659_CR7","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.ccell.2018.02.002","volume":"33","author":"T Maes","year":"2018","unstructured":"Maes T, Mascaro C, Tirapu I, Estiarte A, Ciceri F, Lunardi S, et al. ORY-1001, a potent and selective covalent KDM1A inhibitor, for the treatment of acute leukemia. Cancer Cell. 2018;33:495\u2013511.","journal-title":"Cancer Cell"},{"key":"659_CR8","doi-asserted-by":"publisher","first-page":"4060","DOI":"10.1182\/blood.V128.22.4060.4060","volume":"128","author":"T Somervaille","year":"2016","unstructured":"Somervaille T, Salamero O, Montesinos P, Willekens C, Perez Simon JA, Pigneux A, et al. Safety, phamacokinetics (pk), pharmacodynamics (pd) and preliminary activity in acute leukemia of ORY-1001, a first-in-class inhibitor of lysine-specific histone demethylase 1A (LSD1\/KDM1A): initial results from a first-in-human phase 1 study. Blood. 2016;128:4060.","journal-title":"Blood"},{"key":"659_CR9","doi-asserted-by":"publisher","first-page":"3641","DOI":"10.1016\/j.celrep.2018.03.012","volume":"22","author":"A Maiques-Diaz","year":"2018","unstructured":"Maiques-Diaz A, Spencer GJ, Lynch JT, Ciceri F, Williams EL, Amaral FMR, et al. Enhancer activation by pharmacologic displacement of LSD1 from GFI1 induces differentiation in acute myeloid leukemia. Cell Rep. 2018;22:3641\u201359.","journal-title":"Cell Rep"},{"key":"659_CR10","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1038\/nmeth.3047","volume":"11","author":"NE Sanjana","year":"2014","unstructured":"Sanjana NE, Shalem O, Zhang F. Improved vectors and genome-wide libraries for CRISPR screening. Nat Methods. 2014;11:783\u20134.","journal-title":"Nat Methods"},{"key":"659_CR11","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1126\/science.1247005","volume":"343","author":"O Shalem","year":"2014","unstructured":"Shalem O, Sanjana NE, Hartenian E, Shi X, Scott DA, Mikkelson T, et al. Genome-scale CRISPR-Cas9 knockout screening in human cells. Science. 2014;343:84\u20137.","journal-title":"Science"},{"key":"659_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-014-0554-4","volume":"15","author":"W Li","year":"2014","unstructured":"Li W, Xu H, Xiao T, Cong L, Love MI, Zhang F, et al. MAGeCK enables robust identification of essential genes from genome-scale CRISPR\/Cas9 knockout screens. Genome Biol. 2014;15:554.","journal-title":"Genome Biol"},{"key":"659_CR13","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1016\/j.cell.2015.11.015","volume":"163","author":"T Hart","year":"2015","unstructured":"Hart T, Chandrashekhar M, Aregger M, Steinhart Z, Brown KR, MacLeod G, et al. High-resolution CRISPR screens reveal fitness genes and genotype-specific cancer liabilities. Cell. 2015;163:1515\u201326.","journal-title":"Cell"},{"key":"659_CR14","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1016\/j.cell.2017.02.004","volume":"168","author":"RA Saxton","year":"2017","unstructured":"Saxton RA, Sabatini DM. mTOR signaling in growth, metabolism, and disease. Cell. 2017;168:960\u201376.","journal-title":"Cell"},{"key":"659_CR15","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1126\/science.aao3265","volume":"358","author":"X Gu","year":"2017","unstructured":"Gu X, Orozco JM, Saxton RA, Condon KJ, Liu GY, Krawczyk PA, et al. SAMTOR is an S-adenosylmethionine sensor for the mTORC1 pathway. Science. 2017;358:813\u20138.","journal-title":"Science"},{"key":"659_CR16","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA. 2005;102:15545\u201350.","journal-title":"Proc Natl Acad Sci USA"},{"key":"659_CR17","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1038\/ng.375","volume":"41","author":"H Suzuki","year":"2009","unstructured":"Suzuki H, Forrest AR, van Nimwegen E, Daub CO, Balwierz PJ, Irvine KM, et al. The transcriptional network that controls growth arrest and differentiation in a human myeloid leukemia cell line. Nat Genet. 2009;41:553\u201362.","journal-title":"Nat Genet"},{"key":"659_CR18","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1093\/bioinformatics\/btr260","volume":"27","author":"A Liberzon","year":"2011","unstructured":"Liberzon A, Subramanian A, Pinchback R, Thorvaldsd\u00f3ttir H, Tamayo P, Mesirov JP. Molecular signatures database (MSigDB) 3.0. Bioinformatics. 2011;27:1739\u201340.","journal-title":"Bioinformatics"},{"key":"659_CR19","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.stem.2008.11.015","volume":"4","author":"TC Somervaille","year":"2009","unstructured":"Somervaille TC, Matheny CJ, Spencer GJ, Iwasaki M, Rinn JL, Witten DM, et al. Hierarchical maintenance of MLL myeloid leukemia stem cells employs a transcriptional program shared with embryonic rather than adult stem cells. Cell Stem Cell. 2009;4:129\u201340.","journal-title":"Cell Stem Cell"},{"key":"659_CR20","doi-asserted-by":"publisher","first-page":"6816","DOI":"10.1038\/sj.onc.1210764","volume":"26","author":"AD Friedman","year":"2007","unstructured":"Friedman AD. Transcriptional control of granulocyte and monocyte development. Oncogene. 2007;26:6816\u201328.","journal-title":"Oncogene"},{"key":"659_CR21","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1002\/ajh.2830160309","volume":"16","author":"DR Boggs","year":"1984","unstructured":"Boggs DR. The total marrow mass of the mouse: a simplified method of measurement. Am J Hematol. 1984;16:277\u201386.","journal-title":"Am J Hematol"},{"key":"659_CR22","doi-asserted-by":"publisher","first-page":"6827","DOI":"10.1021\/ja101557k","volume":"132","author":"C Binda","year":"2010","unstructured":"Binda C, Valente S, Romanenghi M, Pilotto S, Cirilli R, Karytinos A, et al. Biochemical, structural, and biological evaluation of tranylcypromine derivatives as inhibitors of histone demethylases LSD1 and LSD2. J Am Chem Soc. 2010;132:6827\u201333.","journal-title":"J Am Chem Soc"},{"key":"659_CR23","unstructured":"Smitheman KN, Severson TM, Rajapurkar SR, McCabe MT, Karpinich N, Foley J, et al. Lysine specific demethylase 1 inactivation enhances differentiation and promotes cytotoxic response when combined with all-trans retinoic acid in acute myeloid leukemia across subtypes. Haematologica. 2018. http:\/\/haematologica.org\/content\/early\/2018\/11\/23\/haematol.2018.199190."},{"key":"659_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/oncsis.2017.76","volume":"6","author":"Y Ishikawa","year":"2017","unstructured":"Ishikawa Y, Nakayama K, Morimoto M, Mizutani A, Nakayama A, Toyoshima K, et al. Synergistic anti-AML effects of the LSD1 inhibitor T-3775440 and the NEDD8-activating enzyme inhibitor pevonedistat via transdifferentiation and DNA rereplication. Oncogenesis. 2017;6:e377.","journal-title":"Oncogenesis"},{"key":"659_CR25","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1038\/leu.2014.119","volume":"28","author":"W Fiskus","year":"2014","unstructured":"Fiskus W, Sharma S, Shah B, Portier BP, Devaraj SG, Liu K, et al. Highly effective combination of LSD1 (KDM1A) antagonist and pan-histone deacetylase inhibitor against human AML cells. Leukemia. 2014;28:2155\u201364.","journal-title":"Leukemia"},{"key":"659_CR26","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.canlet.2017.10.015","volume":"413","author":"S Wen","year":"2018","unstructured":"Wen S, Wang J, Liu P, Li Y, Lu W, Hu Y, et al. Novel combination of histone methylation modulators with therapeutic synergy against acute myeloid leukemia in vitro and in vivo. Cancer Lett. 2018;413:35\u201345.","journal-title":"Cancer Lett"},{"key":"659_CR27","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1111\/bjh.14983","volume":"183","author":"J Sonnemann","year":"2018","unstructured":"Sonnemann J, Zimmermann M, Marx C, Ebert F, Becker S, Lauterjung ML, et al. LSD1 (KDM1A)-independent effects of the LSD1 inhibitor SP2509 in cancer cells. Br J Haematol. 2018;183:494\u20137.","journal-title":"Br J Haematol"},{"key":"659_CR28","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.blre.2017.11.006","volume":"32","author":"L Herschbein","year":"2018","unstructured":"Herschbein L, Liesveld JL. Dueling for dual inhibition: means to enhance effectiveness of PI3K\/Akt\/mTOR inhibitors in AML. Blood Rev. 2018;32:235\u201348.","journal-title":"Blood Rev"},{"key":"659_CR29","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1038\/nature19348","volume":"537","author":"A Olsson","year":"2016","unstructured":"Olsson A, Venkatasubramanian M, Chaudhri VK, Aronow BJ, Salomonis N, Singh H, et al. Single-cell analysis of mixed-lineage states leading to a binary cell fate choice. Nature. 2016;537:698\u2013702.","journal-title":"Nature"},{"key":"659_CR30","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1038\/nri3901","volume":"15","author":"T Weichhart","year":"2015","unstructured":"Weichhart T, Hengstschlager M, Linke M. Regulation of innate immune cell function by mTOR. Nat Rev Immunol. 2015;15:599\u2013614.","journal-title":"Nat Rev Immunol"},{"key":"659_CR31","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.stem.2012.06.009","volume":"11","author":"D Kalaitzidis","year":"2012","unstructured":"Kalaitzidis D, Sykes SM, Wang Z, Punt N, Tang Y, Ragu C, et al. mTOR complex 1 plays critical roles in hematopoiesis and Pten-loss-evoked leukemogenesis. Cell Stem Cell. 2012;11:429\u201339.","journal-title":"Cell Stem Cell"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41375-019-0659-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41375-019-0659-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41375-019-0659-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T17:38:40Z","timestamp":1684604320000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-019-0659-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,28]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["659"],"URL":"https:\/\/doi.org\/10.1038\/s41375-019-0659-6","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,28]]},"assertion":[{"value":"12 February 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"TM is executive director and shareholder of Oryzon Genomics S.A. The authors report no other competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}